2027 Partners

Elanco

Website: www.elanco.com/en-us

Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose™ CSR framework – all to advance the health of animals, people and the planet.

MSD Animal Health

Website: www.msd-animal-health.com

At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com and connect with us on LinkedIn and X (formerly Twitter).

McKinsey & Company

Website: www.mckinsey.com

McKinsey is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth. We work with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. We combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next.

Clinglobal

Website: www.clinglobal.com

Clinglobal is a global, science-based, quality-driven group dedicated to accelerating innovation by providing services and solutions to the animal care industry through the ever-expanding Clinglobal group of companies. Animals are our passion, and people are our strength. Together, we better lives by accelerating animal health innovation.

Our unique business model allows the animal health industry and community to benefit from simplified, comprehensive, and customisable contracting solutions for animal health and nutrition product development and registration.

Our group include companies such as Clinvet (preclinical and lab clinical studies in companion and production animals), Clindata (data management and statistical analysis solutions), Clinomics (molecular biology, clinical pathology and immunology R&D laboratory), rtilab (microbiology and clinical pathology R&D laboratory) and Clinglobal (product development consultancy, regulatory affairs and quality assurance services), as well as an extensive network of strategic partners across geographies and fields of expertise.

Enzene

Website: www.enzene.com

Enzene is an end-to-end CDMO with services spanning discovery, development, and commercial supply, operating integrated sites in Pune (India) and New Jersey (USA). As a pioneer in next-generation biologics technologies, Enzene is disrupting the existing biologics manufacturing paradigm with its patented EnzeneX™ technology—the first fully-connected continuous manufacturing (FCCM) platform validated for commercial biologics supply. We partner with innovators and biosimilar developers to deliver accelerated time-to-market, increased production yields, and cost reductions across a broad range of biologic modalities. Committed to pushing the boundaries of biologics manufacturing innovation, Enzene is striving to reduce monoclonal antibody production costs to below $40 per gram by 2025.

For more information on Enzene, a subsidiary of Alkem Laboratories Ltd, please visit www.enzene.com

knoell

Website: www.knoell.com/en/markets/animal-health

knoell is the only knowledge-based animal health consultancy and clinical studies specialist with its own technical staff based on three continents: North America, Europe, and Asia. This means easy access and broad reach for you as our valued client into the animal health market. It also benefits you by avoiding duplication, providing a better return on investment for valuable data, improving control of expenditure, and reducing administration.

With the arrival of the two well-known and established brands Cyton and Triveritas in the knoell group, knoell was able to expand their business into the animal health market. Both companies have more than two decades of experience in the animal health market in Europe and the USA. The joint activities led to growth of the animal health business in Europe, the US and Asia as well. In order to strengthen its presence in the USA, knoell Animal Health LLC was founded in early 2020. Since February 2021, Triveritas operates as knoell Animal Health Ltd.

With animal health experts working in the US, Europe and Asia and an established network of trusted partners, knoell can support clients' business aspirations better than ever before and provide a truly global service.

Our animal health team offers a full portfolio of services, including start-to-finish product development and ad hoc services.

Sidley Austin

Website: www.sidley.com/en/eu

Sidley’s Global Life Sciences practice takes an integrated, multidisciplinary approach to serving animal health clients worldwide, addressing their full spectrum of legal needs with the goal of enhancing animal health and wellbeing, as well as securing high-quality sources of protein. We draw on our deep industry expertise and understanding of regulators to develop sophisticated strategies for engaging with key authorities, such as the FDA, European Medicines Agency (EMA), European Commission, the UK Veterinary Medicines Directorate (VMD), and China’s National Medical Products Administration (NMPA). We also maintain strong relationships with leading industry bodies, including HealthforAnimals, AnimalHealthEurope, and the National Office of Animal Health (NOAH).

Our highly credible animal health practice is led by Dr. Chris Boyle, a qualified veterinary surgeon and recognised thought leader in the sector, enabling Sidley to support clients in areas such as: promotion of veterinary medicines, commercialisation including discounts and rebate schemes, antitrust/competition law, product recalls, suspension of marketing authorisations by regulators, cross-border and online retail of veterinary medicines, off-label use and compounding, supplementary protection certificates, and regulatory classification of products including borderline issues (e.g. between veterinary medicines, supplements, feeds, medical devices, and pesticides). Our comprehensive practice includes transactional expertise led by Robert Darwin, a prominent M&A, Private Equity, and life sciences lawyer. Robert advises global life sciences corporations and investors on a range of deals, including acquisitions, strategic collaborations, and private equity buyouts. His close collaboration with our regulatory team streamlines due diligence and addresses key regulatory issues for prospective buyers.

Sidley’s Animal Health Legal Forum (AHLF), hosted by our Global Animal Health Practice and Dr Chris Boyle, is a unique network that connects in-house animal health lawyers, regulatory affairs and compliance professionals, and investors. It serves as a platform for discussing the latest industry developments, sharing best practices, and fostering connections within the animal health community.

Syngene International Ltd.

Website: www.syngeneintl.com

Syngene is a leading integrated research, development, and manufacturing partner serving the pharmaceutical, biotechnology, and animal health industries. With world-class infrastructure and compliance with global regulatory standards, we collaborate with animal health innovators to deliver breakthrough solutions that improve the well-being of livestock and companion animals.

Our comprehensive capabilities span small molecules, biologics, and specialty products across the drug lifecycle, from concept to clinic. Syngene’s team of more than 6,000 scientists combines deep expertise with the capacity to deliver exceptional science, robust data security, and world-class manufacturing at speed, helping accelerate time-to-market and reduce the cost of innovation.

Trusted by industry leaders worldwide, Syngene combines scientific excellence with operational agility to accelerate innovation and bring safe, effective products to market faster.

United Animal Health

Website: www.unitedanh.com

United Animal Health, founded in 1956, is a research-driven company that helps protein producers raise healthier animals to feed a growing world. United Animal Health offers livestock nutrition and health products globally through the United Animal Health or affiliate brands. To learn more, visit UnitedAnH.com.

Vido

Website: www.vido.org

The Vaccine and Infectious Disease Organization (VIDO) is one of the world’s largest and most advanced containment facilities and is internationally recognized for its role in infectious disease research and vaccine development. Based at the University of Saskatchewan, VIDO has conducted infectious disease research and vaccine development for almost half a century – commercializing eight vaccines with six being described as ‘world-firsts’. During the COVID-19 pandemic, VIDO tested more than 500 medicines for organizations worldwide. The organization’s 200+ personnel operate using an ISO9001 certified management system. Current infrastructure includes BSL2, BSL3, BSL3-Ag containment with an integrated BSL3 capable GMP vaccine manufacturing facility.  As part of its expansion to enhance pandemic preparedness, VIDO is adding BSL4 capacity and a new BSL2 animal housing facility. This facility will be able to handle a wide range of species, from small disease vectors to bison. VIDO is also an active participant in several international networks, including the CEPI Animal Model Network, INTERCEPTOR, RAV3N, and NATO DIANA, and holds multiple NIH contracts for preclinical animal models and biomanufacturing.